Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes. The system continuously analyzes glucose sensor readings and delivers precise basal and bolus doses via the pump component, with the dual‐hormone configuration also administering glucagon when needed to address hypoglycemic events. This automated approach seeks to smooth glucose fluctuations, minimize hypoglycemia risk and allow users greater flexibility in their daily lives.

Founded in 2015 by engineering and medical researchers from the Massachusetts Institute of Technology and Massachusetts General Hospital, Beta Bionics emerged from pioneering work in closed‐loop glucose control. The company’s founders, including Dr. Ed Damiano, have led multiple clinical trials to evaluate the safety and efficacy of the bionic pancreas concept. Drawing on this research foundation, Beta Bionics continues to advance its regulatory submissions and plans for broader market access.

Beta Bionics primarily serves markets in the United States, where it is conducting pivotal trials to secure regulatory approval for the iLet system. The company’s leadership team combines expertise in medical device development, endocrinology and regulatory strategy, positioning Beta Bionics to address significant unmet needs in diabetes care. Through ongoing product development and strategic partnerships, Beta Bionics aims to bring its automated insulin delivery solution to people living with type 1 diabetes worldwide.

Key Stats

• Today's Range: $13.72 to $14.60
• 50-Day Range: $8.86 to $14.39
• 52-Week Range: $8.80 to $32.71
• Volume: 712,566 shs
• Average Volume: 798,322 shs
• Market Capitalization: $611.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.70
• Consensus Rating: Moderate Buy

Beta Bionics Stock Analysis - MarketRank™

Beta Bionics scored higher than 65% of companies evaluated by MarketBeat, and ranked 303rd out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Beta Bionics has a consensus price target of $19.70, representing about 43.6% upside from its current price of $13.72.

Amount of Analyst Coverage

Beta Bionics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beta Bionics are expected to grow in the coming year, from ($2.22) to ($2.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beta Bionics is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beta Bionics is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beta Bionics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.32% of the float of Beta Bionics has been sold short.

Short Interest Ratio / Days to Cover

Beta Bionics has a short interest ratio ("days to cover") of 7.21.

Change versus previous month

Short interest in Beta Bionics has recently decreased by 8.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beta Bionics does not currently pay a dividend.

Dividend Growth

Beta Bionics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.07

News Sentiment

Beta Bionics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Beta Bionics this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for BBNX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $343,586.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Beta Bionics is held by insiders.

Percentage Held by Institutions

Beta Bionics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/21/2026
• Today: 6/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Beta Bionics: $19.70
• High Price Target: $32.00
• Low Price Target: $11.00
• Potential Upside/Downside: +43.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.20 million
• Net Margins: -60.27%
• Pretax Margin: -60.27%
• Return on Equity: -23.00%
• Return on Assets: -20.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.69
• Quick Ratio: 9.67

Sales & Book Value

• Annual Sales: $100.25 million
• Price / Sales: 6.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.53 per share
• Price / Book: 2.10

Miscellaneous

• Outstanding Shares: 44,560,000
• Free Float: 42,200,000
• Market Cap: $611.36 million
• Optionable: N/A
• Beta: 3.40